Therapeutic antibodies
from EU-approved medicines

Currently, we offer 21 different therapeutic monoclonal antibodies from EU licensed drugs for use in R&D, preclinical development, process development, manufacturing & clinical development. Research-relevant quantities of the original drug are available as aliquot or dilution.

NEW – see our 3 new PD-L1 mAbs:

  • Atezolizumab (Tecentirq®) 
  • Avelumab (Bavencio®)
  • Durvalumab (Imfinzi®)
Therapeutic molecule
Antigen
Filters Sort results
Drug name
Therapeutic molecule
Antigen
Bevacizumab
VEGF-A
Avelumab
PD-L1
Secukinumab
IL 17A
Ramucirumab
VEGFR2
Daratumumab
CD38
Etanercept
TNF-α
Cetuximab
EGFR
Obinutuzumab
CD20
Trastuzumab
HER2
Adalimumab
TNF-α
Durvalumab
PD-L1
Pembrolizumab
PD-1
Rituximab
CD20
Nivolumab
PD-1
Denosumab
RANKL
Infliximab
TNF-α
Tocilizumab
IL-6 R
Golimumab
TNF-α
Ustekinumab
IL-12
Palivizumab
RSV protein F
Atezolizumab
PD-L1

Showing all 21 results